Inhibition of rhotekin exhibits antitumor effects in lung cancer cells

Zhang,Weizhen; Liang,Zhenyu; Li,Jing

doi:10.3892/or.2016.4634

Inhibition of rhotekin exhibits antitumor effects in lung cancer cells

Authors:
- Weizhen Zhang
- Zhenyu Liang
- Jing Li
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: February 24, 2016 https://doi.org/10.3892/or.2016.4634
Pages: 2529-2534
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause for cancer-related death, however, the pathogenesis mechanism is poorly understood. Although the rhotekin (RTKN) gene has been reported to encode an effector for the Rho protein that has critical roles in regulating cell growth, the role of RTKN in lung cancer has not been investigated. In clinical lung cancer patient tumor samples, we identified that the RTKN gene expression level was significantly higher in tumor tissues compared to that of the adjacent normal tissues. To investigate the molecular mechanisms of RTKN in lung cancer, we established RTKN stable knock-down A549 and SPC-A-1 lung adenocarcinoma cell lines using lentiviral transfection of RTKN shRNA and evaluated the antitumor effects. The results showed that RTKN knock-down inhibited lung adenocarcinoma cell viability, induced S phase arrest and increased cell apoptosis. In addition, RTKN knock-down inhibited lung cancer cell invasion and adhesion. Further analysis showed that the S phase promoting factors cyclin-dependent kinase (CDK)1 and CDK2 levels were decreased in RTKN knock-down cells, and that the DNA replication initiation complex proteins Minichromosome maintenance protein complex (MCM)2 and MCM6 were decreased as well in RTKN knock-down cells. These results indicated that the RTKN protein was associated with lung cancer in clinic samples and exerted anticancer activity in lung adenocarcinoma cells through inhibiting cell cycle progression and the DNA replication machinery. These findings suggest that RTKN inhibition may be a novel therapeutic strategy for lung adenocarcinoma.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Peters S, Adjei AA, Gridelli C, Reck M and Kerr K: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7): vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kumar M, Ernani V and Owonikoko TK: Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med. Jul 14–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
4	Black A and Morris D: Personalized medicine in metastatic non-small-cell lung cancer: Promising targets and current clinical trials. Curr Oncol. 19(Suppl 1): S73–S85. 2012. View Article : Google Scholar : PubMed/NCBI
5	Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P and Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 22:3238–3247. 2004. View Article : Google Scholar
6	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
7	Pender A and Popat S: The efficacy of crizotinib in patients with ALK-positive non-small cell lung cancer. Ther Adv Respir Dis. 9:97–104. 2015. View Article : Google Scholar : PubMed/NCBI
8	Reid T, Furuyashiki T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P and Narumiya S: Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J Biol Chem. 271:13556–13560. 1996. View Article : Google Scholar : PubMed/NCBI
9	Bishop AL and Hall A: Rho GTPases and their effector proteins. Biochem J. 348:241–255. 2000. View Article : Google Scholar : PubMed/NCBI
10	Chen M, Bresnick AR and O'Connor KL: Coupling S100A4 to Rhotekin alters Rho signaling output in breast cancer cells. Oncogene. 32:3754–3764. 2013. View Article : Google Scholar
11	Liu CA, Wang MJ, Chi CW, Wu CW and Chen JY: Overexpression of rho effector rhotekin confers increased survival in gastric adenocarcinoma. J Biomed Sci. 11:661–670. 2004. View Article : Google Scholar : PubMed/NCBI
12	Fan J, Ma LJ, Xia SJ, Yu L, Fu Q, Wu CQ, Huang XH, Jiang JM and Tang XD: Association between clinical characteristics and expression abundance of RTKN gene in human bladder carcinoma tissues from Chinese patients. J Cancer Res Clin Oncol. 131:157–162. 2005. View Article : Google Scholar
13	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
14	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
15	Norbury C and Nurse P: Animal cell cycles and their control. Annu Rev Biochem. 61:441–470. 1992. View Article : Google Scholar : PubMed/NCBI
16	Ubersax JA, Woodbury EL, Quang PN, Paraz M, Blethrow JD, Shah K, Shokat KM and Morgan DO: Targets of the cyclin-dependent kinase Cdk1. Nature. 425:859–864. 2003. View Article : Google Scholar : PubMed/NCBI
17	Morgan DO: Principles of CDK regulation. Nature. 374:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
18	Labib K, Tercero JA and Diffley JF: Uninterrupted MCM2-7 function required for DNA replication fork progression. Science. 288:1643–1647. 2000. View Article : Google Scholar : PubMed/NCBI
19	Lygerou Z and Nurse P: Cell cycle. License withheld - geminin blocks DNA replication. Science. 290:2271–2273. 2000.
20	Sahai E and Marshall CJ: ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol. 4:408–415. 2002. View Article : Google Scholar : PubMed/NCBI
21	Watanabe N, Kato T, Fujita A, Ishizaki T and Narumiya S: Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. Nat Cell Biol. 1:136–143. 1999. View Article : Google Scholar : PubMed/NCBI
22	Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y and Narumiya S: p160^ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 404:118–124. 1997. View Article : Google Scholar : PubMed/NCBI
23	Fu Q, Yu L, Liu Q, Zhang J, Zhang H and Zhao S: Molecular cloning, expression characterization, and mapping of a novel putative inhibitor of rho GTPase activity, RTKN, to D2S145-D2S286. Genomics. 66:328–332. 2000. View Article : Google Scholar : PubMed/NCBI
24	Morgan DO: Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
25	Stillman B: Cell cycle control of DNA replication. Science. 274:1659–1664. 1996. View Article : Google Scholar : PubMed/NCBI